William (Bill) Barry
William (Bill) Barry
Principal Statistical Reseach Scientist, Rho, Inc
Dirección de correo verificada de
Citado por
Citado por
Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis
R Barroso-Sousa, WT Barry, AC Garrido-Castro, FS Hodi, L Min, IE Krop, ...
JAMA oncology 4 (2), 173-182, 2018
Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer
ML Telli, KM Timms, J Reid, B Hennessy, GB Mills, KC Jensen, Z Szallasi, ...
Clinical cancer research 22 (15), 3764-3773, 2016
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ...
New England Journal of Medicine 372 (2), 134-141, 2015
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
JF Liu, WT Barry, M Birrer, JM Lee, RJ Buckanovich, GF Fleming, ...
The Lancet Oncology 15 (11), 1207-1214, 2014
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
S Shu, CY Lin, HH He, RM Witwicki, DP Tabassum, JM Roberts, ...
Nature 529 (7586), 413-417, 2016
Significance analysis of functional categories in gene expression studies: a structured permutation approach
WT Barry, AB Nobel, FA Wright
Bioinformatics 21 (9), 1943-1949, 2005
Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus …
LA Carey, DA Berry, CT Cirrincione, WT Barry, BN Pitcher, LN Harris, ...
Journal of Clinical Oncology 34 (6), 542, 2016
A pathway-based classification of human breast cancer
ML Gatza, JE Lucas, WT Barry, JW Kim, Q Wang, M D. Crawford, ...
Proceedings of the National Academy of Sciences 107 (15), 6994-6999, 2010
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401
A Hurria, CT Cirrincione, HB Muss, AB Kornblith, W Barry, AS Artz, ...
Journal of clinical oncology 29 (10), 1290, 2011
Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer
SM Wong, RA Freedman, Y Sagara, F Aydogan, WT Barry, M Golshan
Annals of surgery 265 (3), 581-589, 2017
Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer
SM Tolaney, H Guo, S Pernas, WT Barry, DA Dillon, L Ritterhouse, ...
Journal of Clinical Oncology 37 (22), 1868, 2019
Public knowledge of and attitudes toward genetics and genetic testing
SB Haga, WT Barry, R Mills, GS Ginsburg, L Svetkey, J Sullivan, ...
Genetic testing and molecular biomarkers 17 (4), 327-335, 2013
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
SM Tolaney, Y Boucher, DG Duda, JD Martin, G Seano, M Ancukiewicz, ...
Proceedings of the National Academy of Sciences 112 (46), 14325-14330, 2015
Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line …
HS Rugo, WT Barry, A Moreno-Aspitia, AP Lyss, C Cirrincione, E Leung, ...
Journal of Clinical Oncology 33 (21), 2361, 2015
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
PA Konstantinopoulos, WT Barry, M Birrer, SN Westin, KA Cadoo, ...
The Lancet Oncology 20 (4), 570-580, 2019
Close association of RNA polymerase II and many transcription factors with Pol III genes
D Raha, Z Wang, Z Moqtaderi, L Wu, G Zhong, M Gerstein, K Struhl, ...
Proceedings of the National Academy of Sciences 107 (8), 3639-3644, 2010
Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer
DG Stover, HA Parsons, G Ha, SS Freeman, WT Barry, H Guo, ...
Journal of Clinical Oncology 36 (6), 543, 2018
Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study
Y Sagara, MA Mallory, S Wong, F Aydogan, S DeSantis, WT Barry, ...
JAMA surgery 150 (8), 739-745, 2015
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer
X Wang, T Osada, Y Wang, L Yu, K Sakakura, A Katayama, JB McCarthy, ...
Journal of the National Cancer Institute 102 (19), 1496-1512, 2010
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade …
UA Matulonis, GM Wulf, WT Barry, M Birrer, SN Westin, S Farooq, ...
Annals of Oncology 28 (3), 512-518, 2017
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20